Clinical trials: Obese Subjects
Heart Failure With Preserved Ejection Fraction
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.
- Trial name
- HFpEF (NCT05284617)
- Testing
- HU6
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Obesity
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.
- Trial name
- NCT01666691
- Testing
- Beloranib
- Where
- 3 sites in Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Obesity
Effects of Milk Proteins on Protein Synthesis in Healthy Male Subjects Fed a Hypercaloric, High Sucrose Diet
This study aims at assessing the hypothesis that dietary protein content is a major factor regulating lean body mass gain and energy expenditure during overfeeding, and thus long term body weight gain To test this hypothesis…
- Trial name
- FruMilk (NCT02168218)
- Testing
- 7-day overfeeding
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Lausanne
Obesity, Healthy
Gastrointestinal Tolerability to Agavins and Impact on Host-gut Microbiota-metabolism Interactions Modulation
Agavins are branched neo-fructans and prebiotic fiber found in Agave plants. In preclinical studies, agavins have demonstrated an effect in reversing metabolic disorders associated to overweight and obesity through the modulation…
- Trial name
- NCT04555447
- Testing
- Agavins (prebiotic fiber)
- Where
- 2 sites in Mexico
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional-Unidad Irapuato
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Obesity & Overweight
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways.
- Trial name
- Redefine (NCT07447843)
- Testing
- Redefine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nature's Sunshine Products, Inc.
Ketogenic Diet, Weight Loss
Impact of Exogenous Ketones on Indices of Keto-Adaptation in Obese Subjects on Weight Reducing Diets.
This project will be a three-group controlled 6-wk feeding study where all meals are prepared and provided to obese participants. All participants will be fed a 25% energy-restricted diet.
- Trial name
- STAK (NCT06449287)
- Testing
- Diet, Blood Draw, Ketone/Glucose Monitoring
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Prediabetes
A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects.
The Akkermania muciniphila may play an important role in the occurrence and development of Prediabetes. The purpose of this study was to evaluate the safety and efficacy of AKK in the treatment of Prediabetes among obese…
- Trial name
- NCT05720299
- Testing
- Akkermansia muciniphila, Berberine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yu Chen
Overweight, Obese
AZD7687 Multiple Ascending Dose Study
The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects
- Trial name
- NCT01119352
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Obesity
Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations
The purpose of this study is to compare the use of personalized low-fat meal plans vs. non-personalized low-fat meal plans and the results in body fat reduction in overweight and obese subjects 25 to 45 years of age.
- Trial name
- NCT00487344
- Testing
- Non-Personalized Meal Planning, Personalized Meal Planning and Dietetic Consultation
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Central FITT, Inc
Nocturnal Hypoventilation, Obesity
Prevalence of Nocturnal Hypoventilation in Obese Subjects Fiited With Continuous Positive Airway Pressure for Obstructive Sleep Apnea / Hypopnea Syndrome
CAPNOSOH study is a single-center study conducted at Toulouse University Hospital, aiming to estimate the prevalence of obese and apneic subjects maintaining nocturnal hypoventilation under continuous positive airway pressure…
- Conditions
- Nocturnal Hypoventilation, Obesity, Sleep Apnea Hypopnea Syndrome
- Trial name
- CAPNOSOH (NCT07152990)
- Testing
- Transcutaneous Oxy-Capnography, Quality of life questionnaires, Arterial gasometry
- Where
- France
- Volunteers
- 139 people
- Sponsor
- University Hospital, Toulouse
Obesity, Diabetes
Fibre and Appetite Regulation Trial (FART)
High intake of cereal fibre has been shown to be associated with reduced weight gain and improved insulin sensitivity. We hypothesize these effects are due to the short chain fatty acids derived from the bacterial fermentation…
- Trial name
- NCT00247455
- Testing
- Low fibre breakfast cereal (puffed rice/cornflakes), High fibre cereal (All Bran/Bran Flakes)
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Obesity
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without…
- Trial name
- NCT01560143
- Testing
- Tigecycline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Manjunath Prakash Pai
Insulin Sensitivity
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
- Trial name
- Eritoran2 (NCT02267317)
- Testing
- Eritoran, D5W
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Body-Weight Trajectory
Impact of Health Lifestyle on Body Weight
Pharmacotherapy becomes an important and effective approach to improve body weight. However, it still remains unclear how to manage potential fluctuation after its cessation.
- Trial name
- NCT05608226
- Testing
- Lifestyle Education Program
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 2 Diabetes
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks.
- Trial name
- 1971 (NCT02372630)
- Testing
- Linagliptin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University at Buffalo
Obesity/Overweight
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal renal function and those with mild, moderate or…
- Trial name
- NCT07141030
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Gan & Lee Pharmaceuticals.